Gamida Cell Ltd (GMDA)

Etorro trading 970x250
Gamida Cell Ltd (GMDA) Logo

About Gamida Cell Ltd

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company’s lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel. Address: 5 Nahum Heftsadie Street, Jerusalem, Israel, 91340

Gamida Cell Ltd News and around…

Latest news about Gamida Cell Ltd (GMDA) common stock and company :

Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript
15 Aug, 2022 FinancialContent

GMDA earnings call for the period ending June 30, 2022.

Recap: Gamida Cell Q2 Earnings
15 Aug, 2022 FinancialContent

Gamida Cell (NASDAQ:GMDA) reported its Q2 earnings results on Monday, August 15, 2022 at 07:00 AM. Here's what ...

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update
15 Aug, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022. Net loss for the second quarter of 2022 was $18.6 million, compared to a net loss of $23.6 million in the second quarter of 2021. As of June 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $55.1 million.

Earnings Scheduled For August 15, 2022
15 Aug, 2022 FinancialContent

Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second ...

Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
12 Aug, 2022 FinancialContent

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported ...

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
10 Aug, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).

These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer
09 Aug, 2022 Yahoo! Finance

Does high risk mean high reward? Not necessarily, so say the pros on Wall Street. Specifically citing penny stocks, or stocks that trade for less than $5 per share, analysts advise caution as these names might still be in the early innings, or it could be that they face an uphill battle that is just too steep. Luring investors with their bargain price tags, these stocks might be up against overpowering headwinds or have weak fundamentals. However, analysts argue there are early-stage companies t

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
08 Aug, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company.

How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?
04 Aug, 2022 Yahoo! Finance

The big shareholder groups in Gamida Cell Ltd. ( NASDAQ:GMDA ) have power over the company. Large companies usually...

Recap Of Monday's Biotech Catalysts - End Of the Day Summary
01 Aug, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ: ELDN) Investigational New Drug ...

FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review
01 Aug, 2022 FinancialContent

The U.S. Food and Drug Administration (FDA) has accepted for filing the Gamida Cell’s (NASDAQ: GMDA) Biologics License Application ...

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
01 Aug, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate with breakthrough and orphan drug designations.

Stocks That Hit 52-Week Lows On Monday
25 Jul, 2022 FinancialContent

On Monday, 100 companies reached new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Newmont ...

Stocks That Hit 52-Week Lows On Friday
22 Jul, 2022 FinancialContent

During Friday's session, 61 companies made new 52-week lows. Areas of Interest About Today's 52-Week ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
16 Jun, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now Stock Prodigy Who Found NIO at $2… Says Buy THIS Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

27 Stocks Moving in Thursday's Pre-Market Session
16 Jun, 2022 FinancialContent

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday ...

Gamida Cell to Present Corporate Highlights at the JMP Securities Life Sciences Conference
13 Jun, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Sciences Conference, June 16, 2022 with a presentation at 2:00 p.m. ET in New York, NY.

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors
10 Jun, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Borrello, M.D. to its Board of Directors, effective June 9, 2022. Dr. Borrello is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a renowned physician and author who has made major contributions to better the understanding of immunotherapies and the treatment of hematologic malignancies as well as bone marrow transplant. He will also be joining Gamida Cell’s Science and Technology Committee.

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel
02 Jun, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced completion of the rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant.

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
01 Jun, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the Jefferies Healthcare Conference, June 8, 2022 with a presentation at 11:00 a.m. ET in New York, NY.

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
01 Jun, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced the activation of the initial clinical sites to screen and enroll patients in the company-sponsored Phase 1/2 study evaluating a cryopreserved formulation of GDA-201, a readily available cell therapy candidate for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525). On April 26, 2022, Gamida had announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application and removed the clinical hold for a cryopreserved formulation of GDA-201.

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
17 May, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that company management will present at the upcoming H.C. Wainwright Global Life Sciences Conference. A pre-recorded presentation will become available to registered conference attendees on May 24, 2022 at 7:00 a.m. ET. Management will discuss 2022 catalysts and potential milestones including the U.S. launch opportunity for omidubicel upon potential U.S. Food and Drug Administration approval, accelerating the development of its first-in-class NAM-enabled natural killer (NK) cell therapy candidate, GDA-201, as a potential new approach for patients with follicular and diffuse large B-cell lymphomas, and expansion of its NAM-enabled cell therapy pipeline with multiple next-generation, genetically engineered NK cells.

Gamida Cell Ltd. (GMDA) Q1 2022 Earnings Call Transcript
10 May, 2022 FinancialContent

GMDA earnings call for the period ending March 31, 2022.

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer ...

Gamida Cell: Q1 Earnings Insights
10 May, 2022 FinancialContent

Gamida Cell (NASDAQ:GMDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors ...

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update
10 May, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended March 31, 2022. Net loss for the first quarter of 2022 was $20.2 million, compared to a net loss of $19.2 million in the first quarter of 2021. As of March 31, 2022, Gamida Cell had total cash and cash equivalents of $69.7 million.

Earnings Preview: Gamida Cell
09 May, 2022 FinancialContent

Gamida Cell (NASDAQ:GMDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know ...

Gamida Cell Ltd. (NASDAQ:GMDA): When Will It Breakeven?
05 May, 2022 Yahoo! Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Gamida Cell Ltd.'s...

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022
05 May, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today will share preclinical data at the International Society for Cell & Gene Therapy (ISCT) 2022, being held in San Francisco, CA, May 4-7, 2022 on GDA-301 and GDA-601, two product candidates in the Company’s NAM-enabled genetically modified natural killer (NK) pipeline.

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast
03 May, 2022 FinancialContent

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 10, 2022, at 8:00 a.m. ET to review its first quarter 2022 financial results and provide an update on the company.

Gamida Cell Ltd (GMDA) is a NASDAQ Common Stock listed in , ,

970x250